ArticleItalian journal of pediatrics2026
Value of peripheral blood cell parameters and their derived ratios in predicting intravenous immunoglobulin resistance in Kawasaki disease.
Article in Italian journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveIntravenous immunoglobulin (IVIG) serves as the first-line therapy for Kawasaki disease (KD); however, a significant minority of patients exhibit resistance to this treatment. Currently, there is a lack of easily accessible and reliable predictors for IVIG resistance. This study systematically evaluates the utility of baseline peripheral blood cell counts and their ratios in predicting IVIG non-response.
methodsWe assembled a retrospective cohort from the Children’s Hospital of Chongqing Medical University, including all KD patients admitted between January 1, 2023, and June 30, 2025. Patients were classified as either IVIG-responsive or IVIG-resistant based on the resolution of fever following the initial IVIG treatment. We compared baseline demographics, laboratory data, and coronary artery lesion (CAL) status. Univariable analysis was conducted to identify factors associated with IVIG resistance, and receiver-operating characteristic (ROC) curves were utilized to quantify predictive performance.
resultsAmong the 210 children diagnosed with KD, 15 (7.1%) were classified as IVIG-resistant, while 195 (92.9%) were responsive to treatment. No significant differences were observed in sex, age at onset, or the frequency of CAL between the two groups; however, the hospital length of stay was significantly longer in the resistant cases (P < 0.001). Prior to IVIG treatment, the resistant group exhibited elevated neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), and systemic immune-inflammation index (SII) (P = 0.003, 0.001, 0.013, 0.029, respectively), alongside a lower absolute lymphocyte count (P < 0.001). ROC analysis revealed that NLR (AUC 0.733; cut-off 1.07; sensitivity 100%, specificity 84.6%) and PLR (AUC 0.766; cut-off 64.43; sensitivity 100%, specificity 84.1%) were the most robust pre-treatment predictors of IVIG resistance. Following IVIG administration, responsive patients demonstrated significant alterations in multiple cellular parameters, whereas resistant patients exhibited only minimal changes. The extent of change was markedly different between the groups, particularly for PLR: PLR decreased in resistant patients but increased in responders. The difference in PLR before and after infusion (ΔPLR) provided excellent discrimination (AUC 0.840; cut-off 81.77; sensitivity 93.3%, specificity 90.3%).
conclusionsElevated baseline NLR, PLR, MLR, and SII are identified as risk factors for IVIG resistance in KD. NLR values exceeding 1.07 and PLR values greater than 64.43 demonstrate high predictive value. A decline in post-treatment PLR of ≥ 81.77 serves as an additional strong indicator of non-response to IVIG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.